That the KCNQ2/3-specific inhibitor linopirdine shows no effect in FLO1 cell lines, but they are potently inhibited by the broader acting amitriptyline, not only indicates a key role of a number of other proteins that may be therapeutic targets in GOAs, but also opens up the possibility that patients already taking amitriptyline as an analgesic/antidepressant in cancer may be impacted by its other effects. Here, KCNQ2 is linked to cancer.